Skip to main content

Advertisement

Table 2 Demographic data and baseline characteristics of the study population addressed to severity, frequency and current preventive and abortive medication

From: Saliva molecular inflammatory profiling in female migraine patients responsive to adjunctive cervical non-invasive vagus nerve stimulation: the MOXY Study

Patient No. Migraine type Number of attacks per month Pain intensity (VAS) Score Number of headache days per month Prophylactic medication at baseline Acute medication at baseline
1 CM+ 10 7/10 18 None TRIP + NSAD
2 EM+ 12 5/10 12 ß-blocker + TCA TRIP + NSAD
3 EM− 5 7/10 9 ß-blocker + TCA TRIP
4 EM− 12 8/10 14 None TRIP
5 CM+ 16 8/10 26 None TRIP
6 EM− 7 6/10 9 None TRIP
7 EM+ 2 8/10 8 None TRIP + NSAD
8 EM− 11 7/10 12 None NSAD
9 EM+ 10 8/10 10 Magnesium TRIP + NSAD
10 EM+ 3 8/10 3 SSRI TRIP + NSAD
11 EM+ 8 8/10 14 ß-blocker + TCA TRIP
12 EM− 10 9/10 14 ß-blocker TRIP + ASS
  1. f female, VAS visual analogue scale, CM chronic migraine, EM episodic migraine, ± with/without Aura, TRIP triptans, TCA tricyclic Antidpressants, SSRI Selective Serotonin reuptake inhibitor, NSAD nonsteroidal anti-inflammatory drugs, ASS acetylsalicylic acid, nVNS cervical non-invasive vagus nerve stimulation, preVNS medication remained stable 4 weeks prior to study enrollment (see inclusion criteria)